Virus Diseases

73 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Virus Diseases
Treatment and conditionWhere it standsTrials
9vHPV Vaccine for papillomavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo + Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ansuvimab for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Artesunate for cytomegalovirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Awake timed prone and repositioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
coadministration for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
COVID-19 vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ervebo® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluvoxamine for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
hydroxychloroquine + azithromycin for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for adenoviridae infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immulina for virus diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inmazeb for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for cytomegalovirus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for epstein-barr virus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
mRNA-1018-H5 for influenza in birdsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nirsevimab for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (3 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Position for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
prone positioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Positioning (PP) for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
rabies vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for herpes zosterPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RSVPreF3 OA investigational vaccine for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
S-337395 for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tetanus-Diphtheria booster for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tradipitant for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 high-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 low-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Valganciclovir for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Viral Specific T-cells (VSTs) for virus diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G1.1-NN for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wharton's jelly derived Mesenchymal stem cells. for coronavirus infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for chikungunya feverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for dengueTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for zika virus infectionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zabdeno® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zelicapavir for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1